Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.48
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
BBHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (9)
- Newszacks.com·5d ago·Neutral
Should You Invest in the VanEck Biotech ETF (BBH)? Launched on December 20, 2011, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
View source ↗ - Newszacks.com·25d ago·Negative
ETFs That You May Consider Amid a Strengthening Biotech Outlook Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
View source ↗ - Newszacks.com·30d ago·Positive
Why Healthcare ETFs Are Hovering Around One-Year Highs Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.
View source ↗ - Newszacks.com·32d ago·Neutral
Biotech ETF (BBH) Hits New 52-Week High For investors seeking momentum, VanEck Biotech ETF BBH is probably on the radar. The fund just hit a 52-week high and has risen 41.1% from its 52-week low price of $176.30/share.
View source ↗ - Newsbusinesswire.com·41d ago·Negative
BBH Capital Partners Private Equity Exits The Granite Group NEW YORK--(BUSINESS WIRE)--BBH Capital Partners Private Equity (BBHCP) today announced the successful exit of its investment in The Granite Group (Granite), a diversified distributor of plumbing and HVAC products, in connection with Granite's agreement to be acquired by Watsco, Inc. (NYSE: WSO). Founded in 1971 and headquartered in Concord, New Hampshire, Granite is a third-generation, family-led distributor serving customers across New…
View source ↗ - Newsfool.com·43d ago·Neutral
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
View source ↗ - Newszacks.com·62d ago·Negative
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
View source ↗ - Newszacks.com·67d ago·Neutral
Should You Invest in the VanEck Biotech ETF (BBH)? Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20, 2011.
View source ↗ - Newsseekingalpha.com·90d ago·Positive
BBH: Biotech's Next Growth Cycle Is Just Getting Started VanEck Biotech ETF (BBH) is a Buy, offering concentrated exposure to leading biotech firms entering a new growth cycle. BBH's top holdings—Amgen, Gilead, and Vertex—drive capital appreciation through diversified pipelines, strong cash flows, and expansion into new therapeutic areas. Despite a higher expense ratio and low yield, BBH's risk-reward profile is attractive given enduring demand and robust product pipelines.
View source ↗
Congress trades
- Thomas Suozzihouse · NY03 · disclosed May 20, 2022 (77d later)Sell$50,001 - $100,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 1, 2022 (4d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Jan 1, 2022 (10d later)Buy$1,001 - $15,000
- Thomas Suozzihouse · NY03 · disclosed Nov 5, 2021 (16d later)Buy$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
